The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats

Neurotoxicity Research

Volumn 18, Issue 2, 2010, Pages 151-160

  Cervellini, Ilaria ^a,e   Bello, Ezia ^a   Frapolli, Roberta ^a   Porretta Serapiglia, Carla ^a,c   Oggioni, Norberto ^b   Canta, Annalisa ^b   Lombardi, Raffaella ^c   Camozzi, Francesca ^c   Roglio, Ilaria ^d   Melcangi, Roberto Cosimo ^d   D'incalci, Maurizio ^a   Lauria, Giuseppe ^c   Ghezzi, Pietro ^a,e   Cavaletti, Guido ^b   Bianchi, Roberto ^a,c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Docetaxel; Erythropoietin; Neurophysiology; Pathology; Peripheral neuropathy; Rat; Tumor growth

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; ERYTHROPOIETIN; NEUROPROTECTIVE AGENT; TAXOID;

ADENOCARCINOMA; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; DRUG SCREENING; FEMALE; FISCHER 344 RAT; HUMAN; PERIPHERAL NEUROPATHY; RAT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; ERYTHROPOIETIN; FEMALE; HUMANS; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, INBRED F344; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956687924     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-009-9127-9     Document Type: Article

References (50)

1. Apfel SC (2000) Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest 18:564-573
2. Armstrong T, Almadrones L, Gilbert MR (2005) Chemotherapyinduced peripheral neuropathy. Oncol Nurs Forum 32:305-311
3. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 101:823-828
4. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, Rodriguez-Menendez V, Oggioni N, Canta A, Penza P, Lombardi R, Minoia C, Ronchi A, Cerami A, Ghezzi P, Cavaletti G (2006) Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 12:2607-2612
5. Bianchi R, Gilardini A, Rodriguez-Menendez V, Oggioni N, Canta A, Colombo T, De Michele G, Martone S, Sfacteria A, Piedemonte G, Grasso G, Beccaglia P, Ghezzi P, D'Incalci M, Lauria G, Cavaletti G (2007) Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 43:710-717
6. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489-498
7. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270
8. Braunschweiger PG, Schiffer LM (1980) Growth kinetics of mammary tumor 13762 in rats previously cured by chemotherapy. J Natl Cancer Inst 64:671-674
9. Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484-494
10. Cai F, Helke CJ (2003) Abnormal PI3 kinase/Akt signal pathway in vagal afferent neurons and vagus nerve of streptozotocindiabetic rats. Brain Res Mol Brain Res 110:234-244
11. Campana WM, Myers RR (2003) Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur J Neurosci 18:1497-1506
12. Cavaletti G, Marmiroli P (2004) Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf 3:535-546
13. Cavaletti G, Minoia C, Schieppati M, Tredici G (1994) Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 29:771-776
14. Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G (1997) Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18:137-145
15. Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G (2006) Multicenter assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11:135-141
16. Chattopadhyay M, Walter C, Mata M, Fink DJ (2009) Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 132:879-888
17. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G (2008) The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131:1912-1925
18. Digicaylioglu M, Lipton SA (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-647
19. Djulbegovic B (2005) Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best Pract Res Clin Haematol 18:455-466
20. Elfar JC, Jacobson JA, Puzas JE, Rosier RN, Zuscik MJ (2008) Erythropoietin accelerates functional recovery after peripheral nerve injury. J Bone Joint Surg Am 90:1644-1653
21. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882
22. Ghezzi P, Brines M (2004) Erythropoietin as an antiapoptotic, tissueprotective cytokine. Cell Death Differ 11 Suppl 1:S37-S44
23. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, Brines M (2002) Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99:9450-9455
24. Grasso G, Meli F, Fodale V, Calapai G, Buemi M, Iacopino DG (2007) Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury. Laboratory investigation. J Neurosurg Spine 7:645-651
25. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260
26. Hilkens PH, Verweij J, Vecht CJ, Stoter G, Van Den Bent MJ (1997) Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 8:187-190
27. Juul S (2004) Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol 31:129-142
28. Kennedy WR, Wendelschafer-Crabb G, Johnson T (1996) Quantitation of epidermal nerves in diabetic neuropathy. Neurology 47:1042-1048
29. Keswani SC, Buldanlioglu U, Fischer A, Reed N, Polley M, Liang H, Zhou C, Jack C, Leitz GJ, Hoke A (2004) A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 56:815-826
30. Kuroi K, Shimozuma K (2004) Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer 11:92-99
31. Lauria G, Lombardi R, Borgna M, Penza P, Bianchi R, Savino C, Canta A, Nicolini G, Marmiroli P, Cavaletti G (2005) Intraepidermal nerve fiber density in rat foodpad: neuropathologic-neurophysiologic correlation. J Peripher Nerv Syst 10:202-208
32. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242
33. Li X, Gonias SL, Campana WM (2005) Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury. Glia 51:254-265
34. Lim VS (1991) Recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 18:34-37
35. McCarthy BG, Hsieh ST, Stocks A, Hauer P, Macko C, Cornblath DR, Griffin JW, McArthur JC (1995) Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 45:1848-1855
36. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A (2005) Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7:537-543
37. Nakamura-Craig M, Gill BK (1991) Effect of neurokinin A, substance P and calcitonin gene related peptide in peripheral hyperalgesia in the rat paw. Neurosci Lett 124:49-51
38. Orhan B, Yalcin S, Nurlu G, Zeybek D, Muftuoglu S (2004) Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats. Med Oncol 21:197-203
39. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G (2003) Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9:5756-5767
40. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17
41. Roglio I, Bianchi R, Camozzi F, Carozzi V, Cervellini I, Crippa D, Lauria G, Cavaletti G, Melcangi RC (2009) Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst 14:36-44
42. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635-4640
43. Shang Y, Wu Y, Yao S, Wang X, Feng D, Yang W (2007) Protective effect of erythropoietin against ketamine-induced apoptosis in cultured rat cortical neurons: involvement of PI3K/Akt and GSK-3 beta pathway. Apoptosis 12:2187-2195
44. Siren AL, Fasshauer T, Bartels C, Ehrenreich H (2009) Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6:108-127
45. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G (2005) Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 165:466-469
46. Tillmann HC, Kuhn B, Kranzlin B, Sadick M, Gross J, Gretz N, Pill J (2006) Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 69:60-67
47. Toth C, Martinez JA, Liu WQ, Diggle J, Guo GF, Ramji N, Mi R, Hoke A, Zochodne DW (2008) Local erythropoietin signaling enhances regeneration in peripheral axons. Neuroscience 154:767-783
48. Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21:439-451
49. Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27-46
50. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ (1999) Signal transduction in the erythropoietin receptor system. Exp Cell Res 253:143-156